Table 1 Overview of COVID-19-focused IPD-MAs
First author, last name | Title | Type, status, and availability of data for IPD-MA | Focus | Population | Study design | Treatment/ exposure | Outcome(s) | |
|---|---|---|---|---|---|---|---|---|
1 | Angoulvant [14] | Initial treatment of multisystem inflammatory syndrome in children (MIS-C) and outcomes: a systematic review and meta-analysis of individual patient data; The International MIS-C Treatment Collaborative | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | Children or adolescents | RCTs and non-randomised intervention studies | IVIG plus glucocorticoids or glucocorticoids alone | Cardiovascular dysfunction; mortality; medical intervention rate; mechanical ventilation rate; clinical status; time-to-ICU discharge |
2 | Antwi-Amoabeng [15] | Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review | IPD-MA of published IPD only; Completed and published; Data not available | Pharmaceutical treatment or prophylaxis | Hospitalised patients | Case reports | Tocilizumab | In-hospital mortality; incidence of in-hospital complications; time-to-clinical recovery; inflammatory markers |
3 | Baral [16] | Individual patient data meta-analysis of renin–angiotensin–aldosterone system inhibitors in COVID-19 | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | Hospitalised patients | RCTs and non randomised intervention studies, and longitudinal observational studies | ACEIs or ARBs | In-hospital mortality; ICU admission rate; mechanical ventilation rate; time-to-hospital discharge |
4 | Beyrouti [17] | Characteristics of intracerebral haemorrhage associated with COVID-19: a systematic review and pooled analysis of individual patient and aggregate data | IPD-MA of published IPD only (publication includes AD and IPD); Completed and published; Data included in the publication supplement | COVID-19 outcomes—intracerebral haemorrhage | Hospitalised patients | Any study design | N/A | Mortality, time-to-clinical recovery; discharge location |
5 | Campbell [18] | Predictors of COVID-19 outcomes: an individual participant meta-analysis | IPD-MA; Ongoing | COVID-19 outcomes—long COVID | General population | Any study design other than case reports | N/A | Clinical presentation of long COVID; mortality; rehospitalisation rate; time-to-hospital or ICU discharge, discharge location |
6 | Cao [19] | Comparative efficacy of treatments for patients infected with 2019 novel coronavirus: a systematic review and meta-analysis of individual patient data | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | General population | RCTs and non randomised intervention studies, and longitudinal observational studies | Lopinave/Litonawe | Mortality; time to clinical recovery |
7 | Cao [20] | Comparative effectiveness and safety of antiviral agents for patients with COVID-19: Protocol for a systematic review and individual patient data network meta-analysis | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | General population | RCTs and non randomised intervention studies, and longitudinal observational studies | Antiviral drugs alone or in any combination, including IFN-α, LPV/r, remdesivir, chloroquine, ribavirin, arbidol, and Xuebijing injection | Time to clinical recovery, all-cause mortality; vitals; mechanical ventilation rate; non-invasive ventilation rate; SAEs |
8 | Christophers [21] | Trends in Clinical Presentation of Children with COVID-19: A Systematic Review of Individual Participant Data | IPD-MA of published IPD only; Completed and published; Data included in the publication supplement | SARS-CoV-2 infection clinical presentation | Children or adolescents | Any study design other than case reports | N/A | Clinical presentation of COVID-19 in children |
9 | de Jong [12] | Clinical prediction models for mortality in COVID-19 patients: a living external validation and individual participant data meta-analysis (COVID-PRECISE) | Living IPD-MA; Ongoing | COVID-19 outcomes—mortality | Hospitalised patients | EMRs | N/A | 30-day and in-hospital mortality |
10 | Dominguez-Rodriguez [22] | Management of mechanical circulatory support during the COVID-19 pandemic: an individual patient data meta-analysis | IPD-MA; Ongoing | Non-pharmaceutical clinical treatment | ICU patients | RCTs and longitudinal and cross-sectional observational studies | ECMO | In-hospital and ICU mortality; time-to-hospital or ICU discharge; incidence of VAP, SAEs |
11 | Fontes [23] | Chloroquine/hydroxychloroquine for coronavirus disease 2019 (COVID-19) – a systematic review of individual participant data | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | Hospitalised patients | RCTs only | Chloroquine or hydroxychloroquine | COVID-19-related mortality; All-cause mortality; ARDS incidence; hospitalisation rate; ICU admission rate, time to clinical recovery; time to viral clearance, SAEs |
12 | Gastine [24] | A patient-level meta-analysis on SARS-CoV-2 viral dynamics to model response to antiviral therapies | IPD-MA; Completed and published; Data uploaded to GitHub | Pharmaceutical treatment or prophylaxis | General population | RCTs and longitudinal and cross-sectional observational studies | Antiviral medication | Viral load or clearance |
13 | Goldfeld [25] | Prospective individual patient data meta-analysis: Evaluating convalescent plasma for COVID-19 | IPD-MA; Ongoing | Non-pharmaceutical clinical treatment | Hospitalised patients | RCTs only | Convalescent plasma | Mortality; time to hospital or ICU discharge; COVID-19 severity score |
14 | Harwood [26] | Which children and young people are at higher risk of severe disease and death after hospitalisation with SARS-CoV-2 infection in children and young people: A systematic review and individual patient meta-analysis | IPD-MA of published IPD only; Completed and published; Data not available | COVID-19 outcomes—long COVID or mortality | Hospitalised patients | Cohorts or other longitudinal observational studies | N/A | In-hospital mortality; mechanical ventilation rate; ECMO rate; ICU admission rate |
15 | Hasan [27] | Guillain‐Barré syndrome associated with SARS‐CoV‐2 infection: A systematic review and individual participant data meta‐analysis | IPD-MA of published IPD only; Completed and published; Data not available | COVID-19 outcomes—multiple | General population | Case reports and case series | N/A | Incidence of GBS |
16 | Hong [28] | Efficacy and safety of therapeutic treatments in patients with COVID-19: a network meta-analysis | IPD-MA; Ongoing | Any treatment | General population | RCTs and non randomised intervention studies, and longitudinal observational studies | Any medical or mechanical intervention | Mortality; time-to-hospital discharge; time-to-clinical recovery; viral load; AEs and SAEs |
17 | Juul [29] | Interventions for treatment of COVID-19. A living systematic review with individual patient data meta-analyses, aggregate data meta-analyses, trial sequential analyses, and network meta-analysis (The LIVING Project) | Living IPD-MA; Published and ongoing; Data available from emailing authors | Any treatment | Hospitalised patients | RCTs only | Any medical or mechanical intervention | All-cause mortality; ICU admission rate; renal replacement therapy rate; mechanical ventilation rate; QoL; AEs |
18 | Tan [30] | Prognosis of smell and taste recovery in COVID-19 patients: a systematic review and one-stage meta-analysis of individual patient time-to-event data | IPD-MA; Ongoing | COVID-19 outcomes—neurologic | General population | Cohorts or other longitudinal observational studies | N/A | Time-to-recovery of smell or taste, time taken or extent of improvement of smell or taste |
19 | Korang [31] | Vaccines to prevent COVID-19: a protocol for a living systematic review with network meta-analysis including individual patient data (The LIVING VACCINE Project) | Living IPD-MA; Published and ongoing; Data not available | Vaccine efficacy | General population (limited to those who were never infected with SARS-CoV-2) | RCTs only | Any COVID-19 vaccine | All-cause mortality; COVID-19 incidence; QoL |
20 | Lant [32] | Neurological associations of COVID-19 (COVID-Neuro): A protocol for a systematic review and meta-analysis of individual patient data | IPD-MA; Ongoing | COVID-19 outcomes—neurologic | Hospitalised patients | RCTs and longitudinal and cross-sectional observational studies | N/A | Infection rate; in-hospital mortality; time-to-ICU discharge; time-to-hospital discharge; mechanical ventilation rate; ICU admission rate |
21 | Lee [33] | Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data | IPD-MA of published IPD only; Completed and published; No information on data availability | COVID-19 outcomes—cutaneous | General population | Case reports and case series | N/A | Rate and spectrum of dermatological outcomes |
22 | Ling [34] | Interleukin-6 receptor antagonists for severe coronavirus disease 2019: a meta-analysis of individual participant data from randomised controlled trials | IPD-MA of published IPD only; Completed and published; Data not available | Non-pharmaceutical clinical treatment | Hospitalised patients | RCTs only | IL-6 inhibitors | Time-to-clinical recovery; mortality |
23 | Mallett [35] | At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data | IPD-MA of published IPD only; Completed and published; Data available from emailing authors | SARS-CoV-2 infection diagnosis | Hospitalised patients | Case series and longitudinal studies | N/A | Timing of sample collection for accurate SARS-CoV-2 diagnosis by RT-PCR |
24 | Simmons [36] | Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis | IPD-MA; Completed and published; No information on data availability | Pharmaceutical treatment or prophylaxis | Hospitalised patients | RCTs and non-randomised intervention studies | Sofosbuvir/daclatasvir-based regimens | Clinical recovery within 14 days of randomisation; time-to-clinical recovery; all-cause mortality; time-to-hospital discharge; composite outcome of ICU admission or requirement for invasive mechanical ventilation |
25 | Smith [37] | Protocol for a sequential, prospective meta-analyses [38] to rapidly address priority perinatal COVID-19 questions | Living IPD-MA; Ongoing | COVID-19 outcomes—multiple | Pregnant women | RCTs and longitudinal observational studies | N/A | Adverse birth outcomes; pregnancy-related mortality and morbidity; vertical transmission rate of COVID-19 |
26 | Speich [13] | Efficacy and safety of remdesivir in hospitalised patients with COVID-19: Systematic review and individual patient data meta-analysis of randomised trials | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | Hospitalised patients | RCTs only | Remdesivir | 28- and 60-day mortality; mechanical ventilation rate; duration of mechanical ventilation; clinical status; time-to-clinical recovery; time-to-ICU or hospital discharge; QoL; Viral load or clearance; AEs or SAEs |
27 | Subramaniam [39] | Characteristics and Outcomes of Patients with Frailty Admitted to ICU with Coronavirus Disease 2019: An Individual Patient Data Meta-Analysis | IPD-MA; Completed and published; No information on data availability | COVID-19 outcomes—multiple | ICU patients | Cohorts or other longitudinal observational study only | Frailty | In-hospital mortality; time-to-hospital or ICU discharge; mechanical ventilation rate; non-invasive ventilation rate; ECMO rate; renal replacement therapy rate, vasoactive infusion rate; ICU bed occupancy; discharge location |
28 | Tasoudis[40] | Survival analysis of IL-6 inhibitors versus standard of care for COVID-19: a meta-analysis of individual patient data from randomised trials | IPD-MA of published IPD only; Completed and published; No information on data availability | Pharmaceutical treatment or prophylaxis | General population | RCTs only | IL-6 inhibitors | Mortality; ICU admission rate; hospital discharge rate; mechanical ventilation rate |
29 | Troxel [41] | Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalised With COVID-19: A Meta-analysis | Living IPD-MA; Published and ongoing; No information on data availability | Non-pharmaceutical clinical treatment | Hospitalised patients | RCTs only | Convalescent plasma | 14- and 28-day mortality; COVID-19 severity score |
30 | van Werkhoven [42] | Anytime Live and Leading Interim* meta-analysis of the impact of BCG vaccine in health care workers and elderly during the SARS-CoV-2 pandemic (ALL-IN-META-BCG-CORONA) | Living IPD-MA; Ongoing | Vaccine efficacy | Health care workers; elderly | RCTs only | BCG-vaccine | COVID-19 incidence; hospitalisation rate; infection rate; time to clinical recovery; time to hospital discharge |
31 | Victory [38] | ACEi/ARB medications for hospitalised patients with COVID-19: an individual patient data (IPD)-based pooled analysis | IPD-MA; Ongoing | Pharmaceutical treatment or prophylaxis | Hospitalised patients | RCTs only | ACEIs or ARBs | COVID-19 severity score; time to hospital discharge; duration of mechanical ventilation; 14-day mortality; 30-day mortality, AEs or SAEs |